Beautiful poster and fascinating research from @chriswincup et al showing immune cellular iron deficiency in patients with #SLE. Time to add iron supplementation as part of standard #lupus therapy? https://t.co/Uf81KXbSM0 Abs#0294 #ACR20 @RheumNow https://t.co/z5SUjWFkdD

• Tired T-Cells and Monocytes with Malaise: Investigating the Links Between Cellu…

Abst#0181 out of Korea shows MTX use does not increase prevalence of hepatic steatosis. Encouraging data, though retrospective study may underpin provider bias in riskier patients. #ACR20 @RheumNow. https://t.co/HeR5hroYUh

ANA antibodies in longitudinal #SLE cohort: - 759 patients - 84.8% remained ANA+ve during 5yr followup period - Pts w/ at least one -ve ANA in first 5yrs had milder disease (lower SLEDAI-2K, less steroid, fewer autoantibodies) Abs#0251 #ACR20 @RheumNow https://t.co/U7JbNpJA3w

• Dynamics of Anti-Nuclear Antibodies in a Longitudinal Study of a Large Systemic…

Large data from Japanese Ninja database in abst#0183 shows incidence of malignancies in Japanese RA patients similar to Japanese gen pop. Comparable in patients exposed and unexposed to biologics/JAKs. #ACR20 @RheumNow

15 % of Relapsing Polychondritis meet diagnosis for MAGIC syndrome (Mouth and genital ulcers with inflamed cartilage) - overlap of RP and Behcet's Abst#0425 #ACR20 #ACRbest @RheumNow https://t.co/qaHWwOOL7Q

Great debate by Dr. Weinblatt and Dr. Strand on JAKinibs vs TNFi in RA! How long do you tx with JAKinibs before calling it a failure? @RheumNow #ACR20 #ACRbest

PMR takes fit patients, and drags them down. In this @HSpecialSurgery cohort, PMR patients were more frail: worse physical function, fatigue, and pain - despite a low comorbidity burden. We need to understand the burden of PMR better. IL-6? @SattuiSEMD #ACR20 ABST0422 @RheumNow https://t.co/j6HLNA7ANv

Dr. Weinblatt dodges the question which TNFi prefers after MTX-IR. Which one do you choose? #ACR20 #GreatDebate @RheumNow

Dr.Gonzalez-Mazon describes surrogate markers assoc'd w #atherosclerosis in #axSpA: BASFI, BASMI, IBD, ESR, CRP, prednisone and DMARDs use. @RheumNow #ACR20 abst#0448 https://t.co/g27qA4qpPL

Abst#0135 at #ACR20 illustrates the drivers of patient satisfaction per a survey of 374 U.S. pts. The biggest obstacles to managing RA are pain (80%), fatigue (72%), & depression/anxiety (51%), but only 51% of pts feel that these are addressed. @RheumNow https://t.co/I2ac2T2TOA

The GRA now have >17,000 pts registered! Watch the video link @rheumnow or YouTube: https://t.co/tdp5q7tAPK Please visit the GRA booth @rheum_cat @JYazdanyMD @philipcrobinson @rheum_covid #ACR20 https://t.co/UObvGO3n9Q

• Global Rheumatology Alliance Panel - YouTube
• https://twitter.com/uptoTate/status/1324728442357796864

Agreed- hence the debate is more about patient preference and we need to equip patients with enough information to make correct choices for themselves! @ACRheum @RheumNow #ACR20 https://t.co/zp8HX0YPBV

• https://twitter.com/creakyjoints/status/1324742442470514689

Where one lives matters! Especially during the #COVID19 "flares" - Geographical variations in risk perception and medication management by rheumatologists vary by #COVID19 case burden in the community. Check our abst#0005 #ACR20 @RheumNow

What's your initial biologic of choice when escalating therapy for PsA patients non-responsive to csDMARDs? @RheumNow #ACR20

Extended 5 year study of secukinumab in AS patients showed sustained improvement of back pain, nocturnal back pain, AM stiffness, fatigue and LDA Abs#0364 @RheumNow #ACR20